

Shailendra Kumar Dhar Dwivedi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2564638/publications.pdf>

Version: 2024-02-01

14
papers

524
citations

759233

12
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

1222
citing authors

#	ARTICLE	IF	CITATIONS
1	Cystathionine γ -synthase regulates endothelial function via protein S-sulfhydration. FASEB Journal, 2016, 30, 441-456.	0.5	102
2	Bmi-1: At the crossroads of physiological and pathological biology. Genes and Diseases, 2015, 2, 225-239.	3.4	97
3	Inhibition of BMI1 induces autophagy-mediated necroptosis. Autophagy, 2016, 12, 659-670.	9.1	61
4	Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget, 2016, 7, 15093-15104.	1.8	61
5	Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Molecular Cancer Therapeutics, 2018, 17, 39-49.	4.1	40
6	Micro RNA-195 controls MICU1 expression and tumor growth in ovarian cancer. EMBO Reports, 2020, 21, e48483.	4.5	29
7	MDR1 mediated chemoresistance: BMI1 and TIP60 in action. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 983-993.	1.9	25
8	Cystathione γ -synthase regulates HIF-1 α stability through persulfidation of PHD2. Science Advances, 2020, 6, .	10.3	24
9	Small Non-Coding-RNA in Gynecological Malignancies. Cancers, 2021, 13, 1085.	3.7	20
10	Role of TGF- β 2 signaling in uterine carcinosarcoma. Oncotarget, 2015, 6, 14646-14655.	1.8	20
11	Mitochondrial BMI1 maintains bioenergetic homeostasis in cells. FASEB Journal, 2016, 30, 4042-4055.	0.5	18
12	Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Molecular Cancer Therapeutics, 2018, 17, 2136-2143.	4.1	15
13	Targeting the TGF β 2 pathway in uterine carcinosarcoma. Cell Stress, 2020, 4, 252-260.	3.2	7
14	KRCC1: A potential therapeutic target in ovarian cancer. FASEB Journal, 2020, 34, 2287-2300.	0.5	5